Genus PLC

GNS

Equity

ISIN GB0002074580 / Valor 892328

LSE London Stock Exchange, SETS (2026-09-07)

GBP 22.78+0.62%

Genus PLC
UMushroom community rating:

4.00 2 votes No rating yet

NegativeNeutralPositive

About company

Genus plc is a UK‑based agricultural biotechnology company that develops and supplies commercial animal genetics and related breeding services for the livestock industry, operating mainly through two business units: PIC, which focuses on pig genetics, and ABS, which supplies bovine genetics and reproductive products. The group sells breeding stock, semen, embryos and associated reproductive and genomic services to commercial producers worldwide, using data‑driven breeding programmes and genetic selection to improve traits such as growth and feed efficiency, fertility and disease resilience. Headquartered in the UK and listed on the London Stock Exchange, Genus combines on‑farm supply, research and commercialisation of genetic technologies to generate recurring revenue from product sales and long‑term breeding contracts.

Summarized from source with an LLMView SourceSector: Consumer Non-Cyclicals

Latest Results ():

Summarized from source with an LLMView Source

Key figures

-15.2%1Y

10.5%3Y

-61.9%5Y

Performance

37.7%1Y

41.1%3Y

39.5%5Y

Volatility

2033 M

Market cap (USD)

51,075

Daily traded volume (Shares)

15.32 / 14.92

1 day high/low (USD)

0.00 / 0.00

52 weeks high/low (USD)

01 January, 2022

Dividend ex-date

0.00

Dividend (USD)

0.00%

Dividend yield (p.a.)

0.002022

0.002023

0.002024

Est dividend (USD)

0.00%2022

0.00%2023

0.00%2024

Est dividend yield

10.00

P/E ratio

00.002022

00.002023

00.002024

Est P/E ratio

0.00

EPS (USD)

0.002022

0.002023

0.002024

Est EPS (USD)

Ratings & reviews

4.00

2 votes

Performance:

4.00

Innovation:

5.00

Society:

3.50

Nature:

3.50

Matthew Waterhouse

UK, 18 Feb 2026

Matthew Waterhouse

UK, 03 Feb 2026

Being the market leader in its field of animal genetics creates a dominance that other competitors struggle to compete with. As well as its patents and first mover advantage it holds high upside potential.

EQUITIES OF THE SAME SECTOR

Apotea AB